Nevertheless, these data suggest that the use of CPH:SA MPs did not significantly suppress the anti‐tumor effects of IL‐1α and that further manipulation of the MP dose and dosing schedule may yield significant and durable anti‐tumor effects. This evidence concerns the gene IL1A and neoplasm.